Drug Profile
Pegmusirudin
Alternative Names: LU 57291; PEG-hirudin - Speedel; SPP-200Latest Information Update: 29 Jan 2013
Price :
$50
*
At a glance
- Originator Abbott GmbH & Co. KG
- Class Antithrombotics; Hirudins
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Blood coagulation disorders; Coronary disorders; Unstable angina pectoris; Vascular graft occlusion
Most Recent Events
- 22 Dec 2009 No development reported - Phase-II for Vascular graft occlusion in USA (Parenteral)
- 29 Aug 2006 Speedel has retained all development, commercialisation and marketing rights to pegmusirudin from Abbott Laboratories
- 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories